Germline and Somatic Testing for Ovarian Cancer: An SGO Clinical Practice Statement
(Abstracted from Gynecol Oncol 2024;181:170–178 Identification of germline and somatic pathogenic variants as well as homologous recombination deficiency (HRD) can contribute to the prediction of treatment response, prognostic outcome, and suitability for targeted agents. Germline genetic testing can also serve to inform risk for other malignancies and prompt risk management for at-risk relatives.
Authors
- Leigha Senter (ORCID: https://orcid.org/0000-0001-9270-8847)
- Stephanie V. Blank (ORCID: https://orcid.org/0000-0002-5333-9484)
- Barbara M. Norquist (ORCID: https://orcid.org/0000-0001-5992-7845)
- Renata R. Urban (ORCID: https://orcid.org/0000-0001-8967-3794)
- Maria Klara Frey
- Gregory M. Gressel (ORCID: https://orcid.org/0000-0002-6729-4571)
Institutions
- RCA (United States) (US)
- Faculty of 1000 (United States) (US)
Publication Details
- Journal
- Obstetrical & Gynecological Survey
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1097/01.ogx.0001050548.70397.cb
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00